Home Biosimilar Antibodies Microbiology RSV Motavizumab (Anti-RSV-F)
For research use only. Not for use in humans.

Motavizumab (Anti-RSV-F)

Synonyms: MEDI-524

Motavizumab (Anti-RSV-F) is a monoclonal antibody targeting human RSV (respiratory syncytial virus). It can be used in respiratory syncytial virus infection in high-risk infants research. MW :145.32 KD.

Motavizumab (Anti-RSV-F)

1 Citation

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: Purity: 99% Protein concentration: 7.802mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Motavizumab (Anti-RSV-F) is a monoclonal antibody targeting human RSV (respiratory syncytial virus). It can be used in respiratory syncytial virus infection in high-risk infants research. MW :145.32 KD.
References

Product Details

CAS No. 677010-34-3
Isotype Human IgG1
Source CHO
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00628303 WITHDRAWN Wheezing MedImmune LLC 2010-10 PHASE3
NCT00121108 COMPLETED Healthy MedImmune LLC 2004-11-15 PHASE3
NCT00421304 COMPLETED RSV Illness in ≤12 Months of Participants MedImmune LLC 2007-01-10
NCT00538785 COMPLETED Congenital Heart Disease MedImmune LLC 2005-10 PHASE2
NCT00435227 TERMINATED Participants Less Than 12 Months of Age With RSV Illness MedImmune LLC 2007-03-20 PHASE2
NCT00316264 COMPLETED Respiratory Syncytial Virus Infections; Chronic Lung Disease and <= 24 Months of Age or; Premature With Gestational Age <=35 Weeks and <=6 Months of Age MedImmune LLC 2006-04 PHASE2

(data from https://clinicaltrials.gov, updated on 2012-08-01)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.